

References

I-79

1. Mozobil (plerixafor) for injection [Prescribing Information]. Genzyme Corporation. Cambridge:MA. December 2008. Revised April 2019.
2. Lanza F, Lemoli R, Bosi A, et al. Factors affecting successful mobilization with plerixafor: An Italian prospective survey in 215 patients with multiple myeloma and lymphoma. *Transfusion*. 2014;54(2):331-9.
3. Abdel-Rahman F, Tuffaha H, Hussein A, et al. GCSF with or without chemotherapy compared to plerixafor with GCSF as salvage mobilization regimen in patients with multiple myeloma and lymphoma: Collection effectiveness and cost effectiveness analysis. *J Oncol Pharm Pract*. 2014;20(2):130-6.
4. McDermott D, Liu Q, Velez D, et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. *Blood*. 2014;123(15):2308-16.
5. Dhakal B, Strouse C, D'Souza A, et al. Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. *Biol Blood Marrow Transplant*. 2014;20(12):1926-31.
6. Pantin J, Purev E, Tian X et al. Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: Results of a randomized crossover trial. *Haematologica*. 2017;600-609.
7. Goker H, Etgul S, Buyukasik Y. Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor. *Transfusion and Apheresis Science*. 2015;23-29.
8. MICROMEDEX®SOLUTIONS Compendia. 2017.
9. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Plerixafor.
10. NCCN: National Comprehensive Cancer Network (NCCN). Plerixafor. NCCN Drugs and Biologics Compendium®. 2019.
11. Haverkos BM, Huang Y, Elder P, et al. A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation. *Bone Marrow Transplant*. 2017; 52(4):561–566.
12. Yang X, Wan M, Yu F, et al. Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma: A systematic review and meta-analysis. *Exp Ther Med*. 2019;18(2):1141–1148.